Investor Relations

OPKO Submits Investigational New Drug Application to Initiate a Phase 2a Trial for its Long-Acting Coagulation Factor VIIa-CTP to Treat Hemophilia more »

OPKO and Pfizer Receive Regulatory Clearance for Global Agreement more »

OPKO Launches the 4Kscore Test in Mexico more »

OPKO Claros1 Analyzer Selected for Development of a Rapid Lyme Disease Test Under Immuno Technologies NIH Grant more »

Investor FAQs